In systemic sclerosis (SSc), clinical evidence has shown that Bosentan may foster the regeneration of the peripheral microcirculatory network. The aim of this study was to verify in vitro the influence of Bosentan on the angiogenic performance of dermal microvascular endothelial cells (MVECs) and its possible capacity to counteract the antiangiogenic effects of SSc sera.
Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study / Romano, Eloisa; BELLANDO RANDONE, Silvia; Manetti, Mirko; Bruni, Cosimo; Lepri, Gemma; MATUCCI CERINIC, Marco; Guiducci, Serena. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 33 Suppl 91:(2015), pp. 148-152.
Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study
MATUCCI CERINIC, MARCO;
2015-01-01
Abstract
In systemic sclerosis (SSc), clinical evidence has shown that Bosentan may foster the regeneration of the peripheral microcirculatory network. The aim of this study was to verify in vitro the influence of Bosentan on the angiogenic performance of dermal microvascular endothelial cells (MVECs) and its possible capacity to counteract the antiangiogenic effects of SSc sera.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
